Testosterone

Testosterone is a steroid hormone of the androgen group and the main male sex hormone, with the molecular formula C19H28O2. It is built in the body from cholesterol through a series of enzymatic steps and is secreted mostly by the Leydig cells of the testes; the ovaries and the adrenal cortex produce lesser amounts, and during pregnancy the placenta contributes as well. Circulating testosterone is largely bound to proteins such as sex hormone-binding globulin and albumin, leaving a small free fraction that is biologically active. Its output is governed by the hypothalamic-pituitary-gonadal axis, in which gonadotropin-releasing hormone prompts the pituitary to release luteinizing hormone, which in turn stimulates the testes, with rising testosterone feeding back to restrain the system.

The hormone has wide-ranging effects across the life course. Before birth and during puberty it directs formation of the male genital tract and external genitalia and the emergence of secondary sexual characteristics such as facial and body hair, deepening of the voice, and growth of muscle and bone. In adults it helps maintain sperm production, sexual desire and function, muscle protein synthesis, bone mineral density, and red-blood-cell formation, and it influences mood, energy, and aspects of metabolism ^[1]. Testosterone concentrations are much higher in men than in women and tend to decline gradually with age.

Testosterone was first isolated and chemically characterized in the mid-1930s, and its laboratory synthesis was achieved in 1935 by chemists including Adolf Butenandt and Leopold Ruzicka, work later recognized with a Nobel Prize. As a medicine it is used mainly to treat hypogonadism, a state of clinically low testosterone with matching symptoms, and professional guidelines recommend confirming both consistent symptoms and repeatedly low morning blood levels before starting therapy ^[1]. In symptomatic older men, a coordinated set of randomized trials found that raising testosterone from moderately low into the mid-normal range produced modest gains in sexual activity and desire and small improvements in mood, with no clear benefit for vitality or walking distance ^[2]. A later large safety trial in men with hypogonadism who had or were at high risk of heart disease reported that replacement therapy was not inferior to placebo for major cardiac events, while noting more atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group ^[3].

Medical testosterone is supplied in several forms, including injections, skin gels, patches, and other preparations, and it appears on the World Health Organization's list of essential medicines. Because it can be misused to build muscle and enhance athletic performance, testosterone and related anabolic-androgenic steroids are controlled substances in many countries and are banned by sporting authorities. Guidelines advise against beginning therapy in men seeking near-term fertility or with conditions such as prostate or breast cancer, and recommend monitoring of symptoms, blood testosterone, red-cell count, and prostate health during treatment ^[1].

Supraphysiologic exogenous testosterone reliably suppresses the hypothalamic-pituitary-gonadal axis, shrinking the testes and impairing endogenous production and fertility; a post-cycle recovery protocol is generally needed to restore natural output. It drives erythrocytosis (elevated hematocrit) that raises blood viscosity and thrombotic risk, and it unfavorably shifts the lipid profile by lowering HDL and can raise blood pressure.

Aromatization to estradiol can cause gynecomastia, water retention, and mood swings, while excess androgen load contributes to acne, male-pattern hair loss, and prostate stimulation. Injectable esters spare the liver, but overall cardiovascular strain, polycythemia, and endocrine suppression are the dominant documented risks. Users with cardiovascular disease, uncontrolled hypertension, prostate or breast cancer, or a desire for near-term fertility face the greatest hazard.

Testosterone can potentiate oral anticoagulants; the label documents increased sensitivity to warfarin with a need to reduce anticoagulant dose and monitor INR, an effect attributed to changes in clotting-factor synthesis and warfarin dynamics. Because androgens can improve insulin sensitivity and lower blood glucose, co-administration with insulin or other antidiabetic agents may require dose reduction to avoid hypoglycemia. Concurrent corticosteroids or ACTH increase the risk of fluid retention and edema, particularly in patients with cardiac or hepatic disease. Oral 17-alpha-alkylated forms add hepatotoxicity risk with other hepatotoxic drugs, and testosterone may alter thyroid-binding globulin and related lab values. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Testosterone was first isolated in 1935 by a Dutch-led group of Karoly David, E. Dingemanse, J. Freud and Ernst Laqueur, who purified the hormone from testicular extract and coined its name. Later that same year it was chemically synthesized independently by Leopold Ruzicka with A. Wettstein and by Adolf Butenandt, work for which Ruzicka and Butenandt shared the 1939 Nobel Prize in Chemistry. The synthesis opened the door to modern endocrinology and to therapeutic use of sex hormones. From the mid-twentieth century testosterone and its esters entered clinical use for hypogonadism and later became central to both hormone-replacement medicine and, off-label, athletic performance enhancement.